Are there multiple strains (clades) of the varicella‑zoster virus that cause chickenpox?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Varicella-Zoster Virus Strains and Chickenpox

Yes, there are multiple strains of varicella-zoster virus (VZV), but clinically they all cause the same disease—chickenpox—with no meaningful differences in presentation, severity, or treatment. The virus exists as different genetic variants (clades), but these distinctions are primarily relevant for molecular epidemiology and vaccine development rather than clinical practice 1, 2, 3.

Understanding VZV Strain Variation

Documented Strain Diversity

  • Multiple vaccinia virus strains exist with varying pathogenicity levels (Temple of Heaven, Copenhagen, NYCBOH, WR strain), demonstrating that orthopoxviruses—the family to which VZV belongs—naturally develop strain variants with different virulence characteristics 1.

  • The Oka vaccine strain used in all licensed varicella vaccines was isolated from a single healthy Japanese child in the early 1970s and represents one specific VZV variant that was then attenuated through 31 serial passages in cell culture 1, 2.

  • Wild-type VZV strains circulate globally and establish latency in ganglionic neurons after primary infection, with both wild-type and vaccine-type virus capable of reactivating as herpes zoster 4.

Clinical Implications of Strain Differences

The critical point for clinical practice: all VZV strains cause indistinguishable chickenpox and respond identically to acyclovir therapy 1, 3.

  • Vaccine-type breakthrough varicella presents with milder, atypical disease (fewer than 50 lesions, predominantly maculopapular rather than vesicular) compared to wild-type infection, but this reflects the attenuated nature of the vaccine strain rather than fundamental strain differences 5, 6.

  • The Oka vaccine strain remains susceptible to acyclovir, and treatment protocols do not differ based on whether infection is caused by wild-type or vaccine-type virus 1.

  • No strain-specific diagnostic testing or treatment modifications are required in clinical practice; PCR testing confirms VZV infection but does not routinely differentiate between strains 5.

Why Strain Differences Don't Matter Clinically

Universal Disease Characteristics

  • All VZV strains cause the same pathophysiology: primary infection produces varicella with fever, viremia, and scattered vesicular skin lesions; latency in dorsal root ganglia; and potential reactivation as herpes zoster 3, 4.

  • Severity determinants are host-related, not strain-related: immunocompromised patients, adults, pregnant women, and infants face higher complication risks regardless of which VZV strain causes infection 1, 7, 4.

  • Treatment protocols are identical for all strains: supportive care for healthy children, oral acyclovir (20 mg/kg four times daily) for high-risk groups when started within 24 hours, and IV acyclovir (10 mg/kg every 8 hours) for immunocompromised patients 8, 6.

Vaccine Cross-Protection

  • The single Oka-strain vaccine provides protection against all circulating wild-type VZV strains, demonstrating that antigenic variation between strains is insufficient to escape vaccine-induced immunity 1, 2, 3.

  • Seroconversion rates exceed 97% after vaccination using the Oka/Merck strain, with neutralizing antibodies providing cross-protection against diverse wild-type variants 1.

Common Pitfalls to Avoid

  • Do not order strain-typing or genotyping tests for routine chickenpox cases; these are research tools without clinical utility 5.

  • Do not assume vaccine-type virus is "safer" in immunocompromised patients; disseminated vaccine-strain VZV has caused 39 confirmed cases (28 in immunosuppressed patients), and vaccination remains contraindicated during active immunosuppression 1, 8.

  • Do not attribute treatment failure to strain resistance without documented acyclovir resistance testing; clinical progression despite therapy more commonly reflects delayed treatment initiation (beyond 24 hours), inadequate dosing, or host immunodeficiency 5, 6.

  • Do not confuse VZV strain variation with HSV strain differences; unlike HSV-1 versus HSV-2 (which cause distinct clinical syndromes), VZV strain variants produce identical chickenpox presentations 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Live attenuated varicella vaccine.

Annual review of microbiology, 1996

Research

Varicella-zoster virus.

Clinical microbiology reviews, 1996

Research

Varicella zoster virus infection.

Nature reviews. Disease primers, 2015

Guideline

Herpes Zoster Clinical Presentation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Supportive Care as Primary Treatment for Uncomplicated Chickenpox

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Varicella zoster virus: chickenpox and shingles.

Nursing standard (Royal College of Nursing (Great Britain) : 1987), 2014

Guideline

Management of Chickenpox

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the recommended dosage and administration schedule for the Varicella (chickenpox) vaccine, also known as Capox?
What is the treatment following exposure to shingles?
Can a 3-month-old baby contract varicella-zoster virus (VZV) and develop shingles?
What is the medical term for chicken pox rash on the skin?
What is Varicella (chickenpox)?
Can chronic knee pain or pathology increase the risk of developing hip osteoarthritis in middle‑aged and older adults?
Which sexually transmitted infections should be screened for in a sexually active individual with new, multiple, or anonymous partners?
Can a 13-year-old safely use fluticasone propionate nasal spray, diphenhydramine oral, and azelastine nasal spray together?
What is the recommended adult dosing of imipenem‑cilastatin for acute pancreatitis in patients with normal renal function (creatinine clearance >50 mL/min) and how should the dose be adjusted for impaired renal function?
What is the appropriate treatment for a 57‑year‑old female with low‑density lipoprotein cholesterol 158 mg/dL, total cholesterol 217 mg/dL, triglycerides 186 mg/dL, high‑density lipoprotein cholesterol 46 mg/dL, and non‑high‑density lipoprotein cholesterol 170.7 mg/dL without known atherosclerotic cardiovascular disease?
Should I start calcium carbonate for osteoporosis in an adult patient after confirming low dietary calcium intake and no hypercalcemia, history of calcium‑containing kidney stones, severe chronic kidney disease (eGFR < 30 mL/min), or vitamin D toxicity?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.